Articles with keyword CTLA-4

Immuno-related adverse events of checkpoint inhibitors (G.Yu. Kharkevich, K.V. Orlova)

immune-related adverse events, skin toxicity, colitis, hepatitis,anti-CTLA-4, anti-PD-1, hypophysitis, melanoma

Efficacy of immune checkpoints inhibitors in the treatment of solid tumors (A.A. Rumyantsev, S.A. Tjulandin)

drug therapy, immunotherapy, CTLA-4, PD-1, PD-L1, check-points, programmed cell death protein, nivolumab, pembrolizumab, ipilimumab, atezolizumab, biomarkers, efficacy